Abstract
In May 2023, WHO officially declared the end of the COVID-19 pandemic. Assessing the consequences of the pandemic remains scientifically and practically relevant. Patients who have recovered from COVID-19 are at risk of developing or relapsing tuberculosis (TB). A comparative retrospective-prospective study was conducted on 88 patients with pulmonary TB, including 45 patients after COVID-19. In 68.9% of those examined, COVID-19 was mild. Tuberculomas and focal pulmonary TB predominated in patients. Tuberculomas and focal pulmonary TB predominated in patients. The most common patterns on CT scans were ground-glass and severe changes. Among laboratory parameters, increases in fibrinogen, D-dimer, and C-reactive protein were more often observed. COVID-19, which was mostly mild, did not have a significant impact on the effectiveness of treatment for TB patients. At the same time, such patients had a more frequent development of adverse reactions during anti-tuberculosis chemotherapy and a complicated course of pulmonary TB.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
